Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of January 31, 2022, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 5,388,451,685 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,033,245,735.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of share capital and voting rights as of the reporting date.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,033,245,735) when calculating disclosure thresholds for shareholdings.
- Confirm the number of shares held in Treasury (355,205,950) to understand the difference between issued capital and voting rights.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for financial metrics.